Abstract
Background: Our previous study has demonstrated that small nuclear ribonucleoprotein polypeptides B And B’ (SNRPB) is highly expressed in non-small-cell lung cancer (NSCLC) and functions as an oncogene. However, whether SNRPB contributes to cisplatin resistance in NSCLC is still unknown. This study aimed to explore how SNRPB regulates the effect of cisplatin in NSCLC.Methods: In this study, cell counting kit-8 (CCK-8) and flow cytometry assays were performed to examine cell survival, cell cycle and apoptosis in NSCLC cells upon cisplatin treatment. Western blotting assays were used to examine the cell cycle and apoptosis-related protein expression. The effects of SNRPB on cisplatin-mediated tumor inhibition was measured via a xenograft tumor model in nude mouse.Results: SNRPB negatively regulates cisplatin resistance in NSCLC cells. Knocking out of SNRPB could significantly decrease cisplatin-induced cell growth inhibition, cell cycle arrest and apoptosis in H1299 cells. However, enforced expression of SNRPB in H460 cells can markedly promote cisplatin-induced cell growth inhibition, cell cycle arrest and apoptosis. Our results also indicate that overexpression of SNRPB enhances the inhibitory effects of cisplatin on H460 cell-mediated xenograft tumors.Conclusion: Our results suggest that SNRPB may be a prediction marker for NSCLC patients in response to cisplatin-based chemotherapy.
Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: Implication of c-Src and its inhibitor
